This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
In a rising broad market and a mixed commodity price backdrop, midstream stocks traded up but lagged the S&P 500 and utilities this week. Recent midstream corporation and utility outperformance has helped the Alerian Energy Infrastructure Index (AMEI) cut into the YTD lead the Alerian MLP Index has maintained since the MLP spike in January.
BKEP TGE PAGP SMLP ENB KEY IPL TEP BPL TEGP CEQP NSH OKE.WI EBBNF OKE BIP MMP IPPLF ENBBF BWP NS.PRC ENB NS.PRB PPL SEMG NS NS.PRA
Midstream and MLPs traded well this week, but not as well as you'd expect given a 5%+ oil move and strength in income securities (like utilities). The OPEC meeting Friday turned out to be a catalyst despite no surprise, because of how well-managed expectations were. Oil, energy stocks and MLPs were sharply higher Friday, and the Dow finished positive for the first time in 9 days.
ARLP ETP.PRC OMP CQP KMI.WS ENB NSH KMI.PRA KMI CAPL KMR CVB TRP LNG SRLP ETP SHLX NRP ENBL NS CQH PBA BKEP ETE PAGP WGP TEP TEGP CEQP TRP AMGP OKE PAA KEYUF ENLK OCIP NS.PRC NS.PRB SRE.PRA TCP DM SRE KMLGF CVRR SEMG TRGP KMRFZ NS.PRA
The week started strong, with MLPs up 1.6% Monday, but then followed up with 4 straight negative days, culminating in a big Friday selloff (-2.6%). Friday was the MLP Index's worst day since March 19th, just a few days after the FERC ruling. It was also the worst week for the index since that same week in March. Unlike that week, there wasn't any big midstream news that led to the drop. The action this week was more related to the macro (i.
ETP.PRC CQP DCP XOM PSX PAGP ENB WGP CEQP AM USAC WMB AMGP PAA D CNXM ENB SRE.PRA TCP ETP SRE DM NRP TRGP
Oh, the trials and tribulations of being in the middle. Think of the poor middle child of the family. The elder sibling gets all sorts of attention as parents fret over getting everything right with their first kid. Then the next child comes along and the parents figure that they have this parenting thing down, so they don’t worry as much.
GNE PAGP GNE PAA GEL BPL
You might think institutions with their large staffs of highly-paid and experienced investment professionals would be a force for stability and reason in financial markets. They are not; stocks heavily owned, and constantly monitored by institutions, have often been among the most inappropriately valued.
NEE.PRI NEE.PRJ NEE.PRC PSX CTLR PAGP NEE.PRQ NEE.PRR CLR TRGP NEE
Midstream and MLPs synched up this week to rally 2.7%, outperforming the S&P 500 and utilities, despite renewed oil price angst this week. Midstream stocks and MLPs resumed their recovery after last week's pause, and have now posted gains in 7 of the last 10 weeks. After bottoming in late March, the AMZ and AMEI have posted total returns of 16.2% and 12.3%, respectively. The rally has helped the MLP Index break back into positive territory year-to-date, and the MLP Index closed the week almost exactly at its 200-day moving average (269.
NGL CQP CVI NGL.PRB KMI.WS ENB TGP NSH KMI.PRA KMI WMB EBBNF KMR CVB TRP LNG TGP.PRA TGP.PRB ENB ETP GMLP GLP ENBL NS PBA PAGP EPD WGP SPB CEQP TRP AMGP OKE PAA ENBBF KEYUF ENLK ENLC NS.PRC NS.PRB TCP DM CVRR SEMG KRP SUUIF KMRFZ NS.PRA
The number of institutional holders in Energy Transfer Equity (ETE) had fallen to 433 at the end of the first quarter compared to 438 in the previous quarter.
MS.PRI MS.PRK WMB MS.PRE PAGP MS.PRF MS.PRG MS MS.PRA
Document Table of Contents
FOMO (Fear of Missing Out) hasn’t been much of a problem for energy infrastructure investors over the past year or so. Feelings of WAIL (Why Am I Long?) have been far more common. So the recent rally in the sector has led many investors to enquire why. Earnings only began to be released on Wednesday when Kinder Morgan (NYSE:KMI) announced a 60% dividend increase and $500MM of stock repurchases since December.
KMI.PRA KMI ETE KMI.WS PAGP EPD OKE KMR TEP KMRFZ CVB TEGP
So far in this series, we have discussed the performance of the broader MLP sector, the top MLP gainers, and the top MLP losers in the week ending April 13, 2018. In this part, we’ll discuss the MLP rating updates last week.
NBLX NBL PAGP CVRR MMP PAA SEP
Sanchez Midstream Partners (SNMP) is a midstream MLP involved mainly in natural gathering, processing, and compression. Sanchez Midstream Partners was the top MLP gainer in the week ending April 6, 2018. Sanchez Midstream Partners rallied 16.4%. The company’s YTD (year-to-date) return turned positive due to last week’s gain. Sanchez Midstream Partners has risen 8.6% YTD. Despite the recent gains, Sanchez Midstream Partners has still fallen ~21% in the past year.
TOO TOO.PRE AMID DMLP PAGP CVRR SXE PAA TOO.PRB TOO.PRA FGP SNMP
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET